信達生物-B(01801.HK):達伯舒®聯合力比泰®和鉑類一線治療非鱗狀非小細胞肺癌3期ORIENT-11研究達到預設的主要研究終點
格隆匯1月13日丨信達生物-B(01801.HK)公佈,集團與禮來製藥共同開發的創新PD-1抑制劑達伯舒®(信迪利單抗注射液)的一項在中國的3期臨牀研究(ORIENT-11)-達伯舒®(信迪利單抗注射液)聯合力比泰®(注射用培美曲塞二鈉)和鉑類用於一線治療無EGFR敏感突變或ALK基因重排的晚期或複發性非鱗狀非小細胞肺癌(nsqNSCLC)期中分析達到預設的主要研究終點。
公告稱,基於由獨立資料委員會(IDMC)進行的期中分析,達伯舒®(信迪利單抗注射液)聯合力比泰®(注射用培美曲塞二鈉)和鉑類對比安慰劑聯合力比泰®(注射用培美曲塞二鈉)和鉑類,顯着延長了無進展生存期(PFS),達到預設的優效性標準,信迪利單抗的安全性特徵與既往報導的研究結果一致,無新的安全性信號被確認。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.